Tag: FDA TRI

Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy

LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe,...

Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma

JUPITER, Fla., June 9, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies targeting molecular motors, today announced that the...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsFDA TRI

Decision Notice – CIRO Hearing Panel issues its Reasons for Decision in the matter of Scott Nicolas Zurevinski

The Wait is Over: Hard Rock Hotel & Casino Ottawa Opens with Legendary Guitar Smash and Star-Studded Celebration

BAYOTECH SHIFTS NORTHERN CALIFORNIA HYDROGEN HUB DEVELOPMENT TO NEW SITE TO ACCELERATE IMPACT

Tag: FDA TRI

Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy

Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us